Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4263-4272

  Burke, Patricia A ^a   DeNardo, Sally J ^a   Miers, Laird A ^a   Lamborn, Kathleen R ^b   Matzku, Siegfried ^c   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA5 INTEGRIN; ANGIOGENESIS INHIBITOR; BETA3 INTEGRIN; CILENGITIDE; INTEGRIN; PROTEIN BCL 2; PROTEIN P53; YTTRIUM 90;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; BREAST CANCER; CANCER SURVIVAL; CELL DENSITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; REMISSION; TUMOR VOLUME; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIOIMMUNOTHERAPY; RECEPTORS, VITRONECTIN; SNAKE VENOMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036682030     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts
2. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
3. WAF1/CIP1 in breast epithelial cells
4. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
5. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
6. Bcl-2 is the guardian of microtubule integrity
7. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
8. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines
9. Expression of the protooncogene bcl-2 in prostate and its association with emergence of androgen-independent prostate cancer
10. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse
11. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts
12. Experimental radioimmunotherapy
13. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
14. Antiangiogenic agents and their promising potential for combined therapy
15. Vascular endothelium as the vulnerable element in tumours
16. Integrins: Structure, function and biological properties
17. 3 expression on tumor-associated vessels of human carcinomas
18. 3 blocks human breast cancer growth and angiogenesis in human skin
19. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
20. 3 for angiogenesis
21. The role of vascular cell integrins v3 and v5 in angiogenesis
22. 3: A new prognostic indicator in breast cancer
23. Integrin activation controls metastasis in human breast cancer
24. Arg-Gly-Asp peptide increases endothelial hydraulic conductivity: Comparison with thrombin response
25. In vivo therapy of malignant melanoma by means of antagonists of v integrins
26. 3 integrin in human melanoma cells
27. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
28. 3integrin antagonists: A new class of tracers for tumor targeting
29. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics
30. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
31. N-Methylated cyclic RGD peptides as highly active and selective avb3 integrin antagonists
32. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site
33. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells
34. Monoclonal antibodies raised against human lung carcinomas
35. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody
36. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study
37. p53-independent response of a human breast cancer xenograft to radioimmunotherapy
38. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice
39. 111Indium-1, 4, 7, 10-tetraazacyclododecane-N, N′, N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy
40. Combined modality radioimmunotherapy: Promise and peril
41. 67Cu-2[T-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt’s lymphoma (Raji)
42. Identification of programmed cell death in-situ via specific labeling of nuclear DNA fragmentation
43. Detection of apoptosis in tissue sections
44. Apoptosis. Its significance in cancer and cancer therapy
45. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
46. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
47. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
48. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
49. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts
50. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma
51. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
52. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-Phosphate
53. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts
54. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia
55. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer
56. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
57. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with Taxol chemotherapy
58. 90Yttrium-DOTA-peptide-ChL6
59. 90Y-Lym-1 for Raji lymphoma xenografts
60. Combination vascular targeted and tumor targeted radioimmunotherapy
61. Combined effects of angiostatin and ionizing radiation in autitumour therapy
62. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
63. Antitumor interaction of short-course endostatin and ionizing radiation
64. Potentiation of cytotoxic cancer therapies by antiangiogenic agents
65. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts
66. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
67. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions
68. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
69. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
70. Effect of VEGF receptor inhibitor PTK787/ZK 222548 combined with ionizing radiation on endothelial cells and tumour growth
71. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity
72. 3 during angiogenesis
73. v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice
74. Preferential susceptibility of brain tumors to the antiangiogenic effects of v integrin antagonist
75. 5 antagonist: EMD-121974, EMD-85189
76. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
77. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
78. X-ray-induced P-selectin localization to the lumen of tumor vessels
79. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature
80. 3 integrin, and GPIBα
81. The hemostatic system as a regulator of angiogenesis
82. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas
83. 3 integrin in the activation of vascular endothelial growth factor receptor-2
84. Angiogenesis in hematologic malignancies
85. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression